Biopharmaceutical company Appili Therapeutics has added several clinical research sites in Mexico and Brazil for its Phase III trial to assess Avigan/Reeqonus (favipiravir), its oral therapy for treating mild-to-moderate Covid-19. The expansion is expected to ensure the timely completion of the trial to reaffirm favipiravir as a potential oral Covid-19 antiviral treatment, with top-line results expected in the third quarter of 2021.
The European Medicines Agency has stated that 415 possible cases of rare blood clotting with low platelet count have been reported in the European Economic Area. This is among the 50 million people and more who have been vaccinated with the AstraZeneca and Johnson & Johnson Covid-19 vaccines. Known as thrombosis with thrombocytopenia, the rare blood clotting occurred among 10 individuals who received the J&J shot, and in 405 individuals who were inoculated with the AstraZeneca’s Vaxzevria vaccine.
The Danish health authority has announced that children aged 12 to 15 years will receive Covid-19 vaccines after the adult population has been fully vaccinated by mid-September. The move is an effort to boost the overall immunity of the population against the virus before the winter, the authorities confirmed. Denmark is expected to administer the Pfizer-BioNTech Covid-19 vaccine to adolescents initially, as it is the only EMA-approved vaccine for the age group. The EU drug regulator is expected to authorise the use of Moderna’s Covid-19 vaccine in adolescents in July.